PubMed Health⌕ Search

Biomedical subjects

L König

Publications and source records attributed to L König.

At least 19 recordsLinked to original sources
PubMed1989

[Results of the use of lithium to prevent recurrence of affective psychosis].

The efficacy of lithium treatment in preventing relapse in phasal psychoses was tested by the re-examination of 99 patients at a Dresden clinic whose treatment had on average exceeded ten years. Results and progress were compared with those of patients starting treatment since the introduction of the lithium treatment in the year 1979. Phase or subphase frequency and duration, conditions of treatment, suicide attempts, unfitness for work, and registration as a disabled person were among the aspects considered.

Bipolar Disorder↗
PubMed1988

[Lithium strumas and their psychiatric relevance].

Basing on 172 clinically recorded goitres among 787 patients treated with lithium (21.9%) we studied the question as to whether goitre formation due to lithium has any relevance within the concept of relapse prevention in affective disorders. A statistical comparison of essential disease parameters between the group of patients suffering from struma (goitre) and the total group shows that there is no special type or course of affective disorder with a particular affinity to the development of struma. Likewise, we can conclude from a comparison of treatment course and effectively parameters between both groups that development of struma under influence on the course of treatment or on the efficiency of prophylaxis. The results point to an irrelevance of lithium goitre in respect of psychiatric effects (this does not imply that it is irrelevant in respect of general medical aspects or endocrinology).

Adult↗
PubMed1987

[Clinical trial of contemnol tablets (lithium retard Spofa)].

A report on the clinical testing of the lithium-retard medicament Contemnol (Spofa). It details the way lithium-retard treatment is objectively and subjectively superior to the earlier and still current general lithium treatment.

Administration, Oral↗
PubMed1979

[Psychopharmacotherapy: present status and trends].

The psychotropic preparations developed and introduced in recent years are discussed in the form of a synoptical paper. The information given mainly concentrates on the attempts to find antidepressants without cardiotoxic side-effects, psychoneuroleptics without extrapyramidal side-effects and long-acting or depot preparations. The survey is restricted to psychotropics in a narrow sense (with an antipsychotic action) and to preparations that are produced in the GDR or imported or made available for the clinical testing of which the reporting clinic (Dresden) was in charge.

Antidepressive Agents↗
PubMed1976

[Position of the delayed-action neuroleptic penfluridol (Longperidol/Janssen) in psychiatric therapy].

Longoperidol/Janssen, an orally administered neuroleptic with a five- to seven-day duration of effects, was clinically tested in six mental hospitals in the G.D.R. where the agent was administered to subjects of chronic to subacute schizophrenia. It was not possible for fully consistent results to be obtained in these tests. Workers at mental hospitals in Leipzig and Mühlhausen recommended that the drug should be imported, whereas those at the four other centers (Dresden, Halle, Jena, and Schwerin) did not consider the medication to be indispensable, although they were also able to observe the good effects of the agent.

Delayed-Action Preparations↗
PubMed1976

[Clinical experiences with noxiptilin].

Noxiptilin (Elronon) proved to be a good bipolar thymoleptic agent in the clinical test at 3 special clinics. Its stimulating effect on the psychomotor function is more pronounced than its sedative action. Therefore, in cases with the anxious, agitated depressive syndrome the additional therapy with a neuroleptic agent or a sedative tranquilizer may be favourable. N. is well tolerated even at a higher age. The side effects are the same as those of other known thymoleptics.

Adjustment Disorders↗
PubMed1975

[Clinical experience with Leponex].

Until now the "neuroleptic threshold" (Haase) was considered to be the efficiency criterion of the antipsychotic effect of a neuroleptic substance and it was thought therefore that the extrapyramidal symptoms were a necessary although undesired side effect. The benodiazepine derivative Leponex developed by Sandox - Basel upsets this view because it has an excellent antipsychotic effect without creating definite extrapyramidal symptoms. It is noted for its quick soporfic effect after only a few minutes, for subdueing psychopathological productivity in a very impressive way, for acting rapidly on the "plus"-symptomatology typical of psychosis, as early as in the first days of treatment, and for its equally visible effect on the "minus"-symptoms, typical of psychosis, in the last third of an average period of treatment lasting 40 days. The clinic using Leponex (Dresden, Halle, Brandenburg-Görden) belonged to the clinical application programme of the Sandox - Basel firm. The article gives a summary of essential results and particulars about the treatment. A detailed evaluation of the case sheets which are at present being statistically reviewed will be given in the next paper.

Adult↗
PubMed1975

[Neuroleptic long term care with extremely low doses in psychotic syndromes of paranoid-hallucination type].

About 30 patients with, in some cases, recurring paranoid or paranoid-hallucinatory psychoses underwent a long-term treatment--from 2--6 years according to individual cases--with very small doses of powerful neuroleptics (Haloperidol, Triperidol, and occasionally Trisedyl). Relapses, such as remanifestations, which occured in some cases, were easily controlled either in outpatients or in the day clinic. No extrapyramidal symptoms of pharmacogenic defect syndromes were observed. The rehabilitation successes were in part very good to exceptional.

Dose-Response Relationship, Drug↗
PubMed1975

[Experiences in the long term use of the 24 hour effective neuroleptic "pimozide" (Janssen)].

Pimozid (R 6238 Janssen, Beerse), a neuroleptic similar to the Butyrophenon type has a 24-hour period of effect due to the substance, and was used from 1969 onward on a total of 39 patients, predominantly from the range of schizophrenia types. The objective of thus clinical study was, above all, to plot the extent of its effects, define the optimal range of indications, to determine the most favourable dosage profile and to examine its tolerance in long-term use. Objectifying the medicinal effects, for example recording the psychopathological findings, proved successful with the aid of a syndrom catalogue following the AMP system, in comparison with preceeding and following treatments and considering the social-psychiatric aspects, so that concomitant- and side effects can be ascertained in the same way. The necessary maintenance dose of Pimozid, usually administered once a day, was set in relation to the daily dosage of Haloperidol, which had to be administered 2 to 3 times daily; the results, meanwhile, were compared with those already recorded on the literature. In agreement with this Pimozid proved to be a powerful and well tolerated neuroleptic, even in older patients, with a constant 24-hour effect which is suitable in doses from 1--10 mg/d particularly for long-term out-patient therapy, and above all for psychotics of the paranoid hallucinatory type.

Adolescent↗